

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DINGDANG HEALTH TECHNOLOGY GROUP LTD.

叮嚙健康科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 09886)

PROFIT ALERT – NARROWING OF LOSS

This announcement is made by Dingdang Health Technology Group Ltd. (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary assessment of the unaudited management accounts of the Group for the six months ended June 30, 2023 (the “**Period**”), the Group expects that as the fair value losses on the Company’s shares with preferred rights (which were preference shares issued to pre-IPO investors) as financial liabilities at fair value through profit or loss (“**FVTPL**”) and listing expenses did not recur for the Period after the completion of the Company’s listing of its shares on The Stock Exchange of Hong Kong Limited in September 2022 (the “**Listing**”) and the decrease in share-based payments during the Period, the net loss for the Period may be narrowed by more than 70% as compared to the net loss of RMB586 million for the corresponding period in 2022.

The Company is still in the process of finalizing the interim results of the Group for the Period. The information contained in this announcement is only a preliminary assessment by the Board based on the figures and information currently available, and is not audited or reviewed by the auditor or the audit committee of the Company and may differ with the actual interim results of the Group for the Period. Shareholders and potential investors of the Company should refer to and carefully read the interim results announcement of the Company for the Period, which is expected to be published in August 2023.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
DINGDANG HEALTH TECHNOLOGY GROUP LTD.
YANG WENLONG
Chairman

Hong Kong, August 9, 2023

As of the date of this announcement, the executive Directors are Mr. YANG Wenlong, Mr. XU Ning, Mr. YU Lei and Mr. YU Qinglong, the non-executive Director is Ms. CAI Li, and the independent non-executive Directors are Mr. ZHANG Shouchuan, Mr. FAN Zhenhong and Mr. JIANG Shan.